Cómo la IA está revolucionando el desarrollo de fármacos

The article highlights a paradigm shift in pharmaceutical research driven by the massive generation of high-quality scientific data. Companies like Terray Therapeutics are transitioning from traditional, slow manual methods to highly automated laboratories that produce terabytes of biochemistry data daily. This influx of precise molecular information allows artificial intelligence models to learn patterns and predict drug candidates with unprecedented speed, significantly reducing the time and costs associated with early-stage discovery. The core relevance to open_data lies in the necessity of accessible, structured scientific datasets to train these AI systems effectively. The success of AI in drug discovery depends entirely on the quality and volume of available data, moving beyond generic internet information to specialized, rigorous biochemical measurements. When companies like Terray release open-source versions of their models or share data, they lower barriers for innovation, enabling broader collaboration and accelerating the collective ability to decode complex biological interactions. Ultimately, the implication is that data transparency and standardization are critical for solving historical inefficiencies in drug development, such as high failure rates in clinical trials. By leveraging open and shared data ecosystems, the industry aims to improve prediction accuracy and reduce the billions spent on failed candidates. This approach not only enhances the likelihood of finding effective treatments but also democratizes access to advanced AI tools, fostering a more agile and cost-effective healthcare innovation landscape.

Source: diario.mx
Published on 2024-06-18

CNHA releases new Maui recovery statistics - The Garden Island »

Datos Abiertos (Open data)

Related news